APVO Key Statistics, Chart & Performance
The current stock price of APVO is 1.16 USD. In the past month the price decreased by -20%. In the past year, price decreased by -98.53%.
APVO Latest News, Press Relases and Analysis
APVO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.86B | ||
| AMGN | AMGEN INC | 14.51 | 170.90B | ||
| GILD | GILEAD SCIENCES INC | 15.04 | 152.86B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.69 | 113.14B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.59 | 78.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.08 | 54.51B | ||
| INSM | INSMED INC | N/A | 41.64B | ||
| NTRA | NATERA INC | N/A | 31.89B | ||
| BIIB | BIOGEN INC | 10.3 | 25.31B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.51 | 21.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.97 | 18.87B |
Related stock screener links
About APVO
Company Profile
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 37 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Company Info
APTEVO THERAPEUTICS INC
2401 4th Ave Ste 1050
Seattle WASHINGTON 98121 US
CEO: Marvin L. White
Employees: 37
Phone: 12068380500
APTEVO THERAPEUTICS INC / APVO FAQ
What does APTEVO THERAPEUTICS INC do?
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 37 full-time employees. The company went IPO on 2016-07-20. The firm has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The firm has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
What is the current price of APVO stock?
The current stock price of APVO is 1.16 USD. The price decreased by -3.33% in the last trading session.
Does APTEVO THERAPEUTICS INC pay dividends?
APVO does not pay a dividend.
What is the ChartMill rating of APTEVO THERAPEUTICS INC stock?
APVO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does APTEVO THERAPEUTICS INC have?
APTEVO THERAPEUTICS INC (APVO) currently has 37 employees.
Can you provide the short interest for APVO stock?
The outstanding short interest for APTEVO THERAPEUTICS INC (APVO) is 4.63% of its float.
APVO Technical Analysis
APVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APVO. APVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
APVO Financial Highlights
Over the last trailing twelve months APVO reported a non-GAAP Earnings per Share(EPS) of -1745.46. The EPS increased by 87.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -103.54% | ||
| ROE | -160.72% | ||
| Debt/Equity | 0 |
APVO Forecast & Estimates
7 analysts have analysed APVO and the average price target is 428.4 USD. This implies a price increase of 36831.03% is expected in the next year compared to the current price of 1.16.